Key facts
- Dx4Life’s last known valuation is $3.8M (Dec 2024).
- It has raised $580K; the latest was Early Stage VC ($580K) in Dec 2024.
- Notable investors include GOBIA Enterprises, LU Innovation (Lund), SmiLe Incubator.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Dx4Life
- ·The full record, as it builds
Funding rounds
No funding rounds for Dx4Life are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dx4Life
Developer of a hormone treatment designed to detect pregnancy chances. The company provides a biomarker that reliably determines what hormone treatment each patient should have radically improving the odds of pregnancy, enabling fertility clinics to offer each patient the right hormone treatment before IVF.
- Sector
- Healthcare
- HQ
- Stockholm, Sweden
- Founded
- 2024
- Employees
- 1
- Website
- dx4life.org/
- Ownership
- Privately Held (backing)
Dx4Life doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dx4Life shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dx4Life in its N-PORT filings yet. We sweep new filings monthly.